Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, 6-1, Kishibe-shimmachi, Suita, Osaka, 564-8565, Japan.
Department of Cardiovascular Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Gen Thorac Cardiovasc Surg. 2023 May;71(5):291-298. doi: 10.1007/s11748-022-01872-w. Epub 2022 Sep 21.
The early and long-term outcomes after pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) have been established by several high-volume centers, but the impact of postoperative residual pulmonary hypertension affecting postoperative clinical parameters remains unclear. This study aims to investigate the institutional surgical results of PEA and to evaluate the efficacy of additional balloon pulmonary angioplasty (BPA) for residual pulmonary hypertension.
We retrospectively reviewed 222 patients (57.7 ± 12.9 years old, 141 female) who underwent PEA for CTEPH at the National Cerebral and Cardiovascular Center between 2000 and 2020.
The preoperative mean pulmonary artery pressure (mPAP) was 45.6 ± 9.7 mmHg and pulmonary vascular resistance (PVR) was 1062 ± 451 dynesec/cm. Postoperative mPAP (23.4 ± 11 mmHg, 204 patients, P < 0.001) and PVR (419 ± 291 dynesec/cm, 199 patients, P < 0.001) significantly improved after PEA. Since 2011, 62 patients (28%) underwent BPA after PEA for "catecholamine dependent" residual PH 1 month after PEA in 14, "scheduled" BPA with residual PH 1 year after PEA in 32, and 16 "symptomatic" patients without residual PH. Their mPAP had significantly improved by PEA (48.1 ± 7.7 to 32.0 ± 10.2 mmHg, P < 0.001), and further improved (33.8 ± 11.1 to 26.5 ± 9.1 mmHg, P < 0.001) after BPA.
PEA provided immediate and substantial improvements in pulmonary hemodynamics and favorable long-term survival. In addition, postoperative BPA improved postoperative clinical parameters for eligible patients regardless of the presence of residual PH.
多家大容量中心已经确定了慢性血栓栓塞性肺动脉高压(CTEPH)患者行肺动脉内膜剥脱术(PEA)后的早期和长期预后,但术后残余肺动脉高压对术后临床参数的影响尚不清楚。本研究旨在探讨 PEA 的机构手术结果,并评估附加球囊肺动脉成形术(BPA)治疗残余肺动脉高压的疗效。
我们回顾性分析了 2000 年至 2020 年期间在日本国立循环器病研究中心接受 PEA 治疗 CTEPH 的 222 例患者(57.7±12.9 岁,141 例女性)。
术前平均肺动脉压(mPAP)为 45.6±9.7mmHg,肺血管阻力(PVR)为 1062±451dynesec/cm。PEA 后 mPAP(23.4±11mmHg,204 例患者,P<0.001)和 PVR(419±291dynesec/cm,199 例患者,P<0.001)显著改善。自 2011 年以来,62 例患者(28%)在 PEA 后因“儿茶酚胺依赖性”残余 PH 而接受 BPA,其中 14 例在 PEA 后 1 个月,32 例因“计划”残余 PH 而接受 BPA,16 例因无残余 PH 而接受“症状性”BPA。他们的 mPAP 在 PEA 后显著改善(48.1±7.7 至 32.0±10.2mmHg,P<0.001),并且在 BPA 后进一步改善(33.8±11.1 至 26.5±9.1mmHg,P<0.001)。
PEA 即刻显著改善肺血流动力学,长期生存良好。此外,术后 BPA 改善了适合患者的术后临床参数,无论是否存在残余 PH。